Morgan Stanley shares remain pressured as recovery falters below resistance: weekly analysis

Morgan Stanley shares remain pressured as recovery falters below resistance: weekly analysis
Morgan Stanley slips 5.70% this week

Shares of Morgan Stanley (MS) are trading near $202 after slipping nearly 6% over the past week, as momentum tilts sharply negative and oversold signals emerge on the chart. A lack of sustained recovery continues to keep downside pressure in play for the days ahead, with technical readings resembling a stretched decline.

MS price prediction
24H -1.2%
$179.35
48H -1.21%
$179.32
7D -5.49%
$171.56
1M -14.61%
$155
3M -8.28%
$166.49
6M -9.08%
$165.04
12M 14.91%
$208.58
Current price: $181.52 -5.1400 2.75%
Real-time Data 15:35
Daily range 178.20 Arrow from to Icon 183.55
Weekly range 186.27 Arrow from to Icon 193.19
Loading...

Highlights

  • Shares of Morgan Stanley fell 5.7% over the past week, ending at $202.16 with momentum pointing lower.
  • The stock trades below both its 20-day and 50-day moving averages, indicating a sustained bearish short-term structure.
  • The next five days are expected to see shares move between $194.45 and $209.86, with a 73% chance of further decline and key support at $200.4.

Innovation and social impact initiatives draw little short-term investor response

Morgan Stanley announced its selection of 20 startups for its 2026 global cohort, with each startup receiving a $150,000 equity investment, while four nonprofits will also benefit from grants and mentorship, according to stocktitan.net. This initiative highlights MS's ongoing efforts in innovation and social impact capital, yet is not expected to materially shift investor sentiment in the short term.

Morgan Stanley asset chart
Morgan Stanley price dynamics. Source: TradingView.

Downside momentum intensifies as volatility spikes and support is tested

The daily chart shows a sharp move lower without a sustained trend, with 7-day volatility at 8.6%. Momentum is tilted to the downside, as signaled by a CCI reading deep in the oversold zone at -237.33 and Stochastic RSI pinned to zero. The nearest support is at $200.4, while resistance aligns with the Ichimoku Kijun at $211.2. This combination keeps the setup vulnerable to further downside, though an oversold backdrop could support a temporary bounce.

Consolidation seen likely as downside bias dominates next week

For the next five trading days, Morgan Stanley is expected to trade between $194.45 and $209.86. There is a 73% probability of a decrease versus 27% for an advance, as the provider’s direction remains down. The base case is consolidation within the $194.45–$209.86 range. A decisive move above $211.2 would shift the short-term picture more positive, while a break below $200.4 opens the door to further losses toward the lower boundary of the expected range.

Jainam Mehta, market strategist, notes that shares of Morgan Stanley remain under pressure this week, sliding nearly 6% to trade near $202 as daily momentum and volatility both signal a bearish undertone. Technically, the charts indicate oversold extremes, with CCI at -237.33 and Stochastic RSI pinned to zero, but the lack of a sustained recovery keeps the risk of further downside alive. Mehta also highlights the company’s recent selection of 20 startups for its 2026 global cohort and associated social impact grants, but does not see this news shifting short-term sentiment given the prevailing technical setup. "With resistance at $211.2 and support near $200.4, I expect consolidation between $194.45–$209.86 in the coming days, while a decisive break of these levels will likely define the next move."

Earlier, analysts noted that Morgan Stanley was exhibiting downside momentum with persistent technical pressures limiting the likelihood of a near-term rebound. The latest readings reinforce this prevailing scenario, highlighting $200.4 as the critical support level to monitor as price action remains vulnerable to further declines within the established range.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.